共 50 条
- [31] A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2016, 22 (06) : 1348 - 1355Papadopoulos, Kyriakos P.Kelley, Robin KateTolcher, Anthony W.Razak, Albiruni R. AbdulVan Loon, KatherinePatnaik, AmitaBedard, Philippe L.Alfaro, Ariceli A.Beeram, MuralidharAdriaens, LieveBrownstein, Carrie M.Lowy, IsraelKostic, AnaTrail, Pamela A.Gao, BoDiCioccio, A. ThomasSiu, Lillian L.
- [32] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Perets, RuthGeva, RavitMcKean, MeredithGoutopoulos, AndreasErez, OmriPhadnis, MonicaYoussoufian, HagopSchwartz, Brian E.Kansra, VikramFattaey, Ali
- [33] A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Papadopoulos, Kyriakos P.Ahnert, Jordi RodonKhushman, Moh'd M.Sharma, SunilPelster, MeredithCecchini, MichaelKummar, ShivaaniChoi, MinjungAkella, Lalith V.Garofalo, AmandaYu, ZiyangIyer, VarshaNguyen, Marie HuongOrford, Keith W.Klempner, Samuel J.
- [34] A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Sommerhalder, DavidPiha-Paul, Sarina A.Pelster, MeredithBorad, Mitesh J.Vandross, Andrae LavonSpira, Alexander I.Perez, SamanthaBrinton, LindseyKelly, KimberlyRamanathan, Ramesh K.Reilley, Matthew
- [35] A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Gabrail, Nashat Y.Hamilton, Erika P.Elias, Anthony D.Rimawi, Mothaffar F.Li, ChaoCorvez, Maria MargaritaLi, WeiFeng, YingWei, JiaoGreene, StephaniePatterson, JohnZeng, QingpingHui, Ai-Min
- [36] A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid TumorsEUROPEAN JOURNAL OF CANCER, 2012, 48 : 11 - 12Smith, D. C.Chugh, R.Patnaik, A.Papadopoulos, K.Chambers, G.Thorpe, V.Xu, L.Kapoun, A. M.Dupont, J.Tolcher, A.
- [37] A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Tolcher, Anthony W.Chugh, RashmiChambers, GlendaThorpe, VilletteDupont, JakobHill, DawnXu, LuKapoun, AnnSmith, David C.
- [38] A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Ahnert, Jordi RodonTaylor, Matthew H.O'Reilly, Eileen MaryZhang, JingsongDoebele, Robert CharlesBen, YongSharp, Leslie L.Boyle, William J.Chang, CathyFrey, GerhardChen, WeiMelnick, MichaelShort, Jay M.Burris, Howard A.
- [39] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Papadopoulos, Kyriakos P.Jonasch, EricZojwalla, Naseem J.Wang, KeshiBauer, Todd Michael
- [40] IGNYTE: AN OPEN-LABEL, MULTICENTER, PHASE 1/2 (PH 1/2) CLINICAL TRIAL OF RP1 ± NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A538 - A538Middleton, MarkMilhem, MohammedAroldi, FrancescaSacco, JosephVanderWalde, AriBaum, ScottSamson, AdelChesney, JasonNiu, JiaxinRhodes, TerenceBowles, TawnyaEmamekhoo, HamidTsai, KatyIn, GinoBeasley, GeorgiaChmielowski, BartoszDalac-Rat, SophieKahler, KatharinaMunoz, EvaOlsson-Brown, AnnaBommareddy, PraveenMenezes, LavitaPirzkall, AndreaCoffin, RobertHarrington, Kevin